The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction
Authors' conclusion
Elucidating a role for an SGLT2i in suppressing sterile inflammation will enhance understanding of how they can be used effectively to treat cardiorenal complications and will identify novel pathways for future intervention. Furthermore, the optimal timing of when to initiate SGLT2i therapy post-AMI is unclear. Correlating the level of protection to the onset of therapy in individuals with T2DM, AMI and at cardiovascular risk will establish if Empagliflozin provides greater benefit when intervention is initiated earlier.
Study context
- Population
- Patients with T2D who have recently had an acute myocardial infarction (AMI); plasma and monocyte-derived macrophages
- Comparison
- Empagliflozin initiated immediately after AMI vs at 3 months post-AMI
Methodological detailsrandomisation
- Randomisation
Primary result
As reported in the abstract
- Protocol; no results reported. Hypothesis: Empagliflozin suppresses systemic NLRP3 inflammasome activation and pro-inflammatory senescence-associated secretory phenotype (SASP); benefits of early intervention will also be assessed
Original publication
The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction. Diabet Med. Published 25 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →